The Combination of Aldehyde Dehydrogenase 1 (ALDH1) and CD44 is Associated with Poor Outcomes in Endometrial Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Oct 30

PMID 30372483

Citations 12

Authors

Hsin-Hui Huang

Yu-Chi Wang

Yu-Ching Chou

Mu-Hsien Yu

Tai-Kuang Chao

Affiliations

Soon will be listed here.

Abstract

Aldehyde dehydrogenase 1 (ALDH1) and CD44 have been established as biomarkers for predicting the survival of many types of cancer patients. This study evaluated the expression and clinical significance of these putative cancer-cell markers in a series of tumor samples from endometrial cancer (EC) patients using tissue microarray. We examined 245 endometrial samples, including 132 (53.87%) pre-malignancy lesions and 113 (46.12%) malignant endometrial lesions from biopsies or hysterectomies. We examined the expression of CD44 and ALDH1 in these samples using immunohistochemistry staining. Correlations in the relative expression of these markers with clinicopathological parameters were also assessed. A high level of expression of ALDH1 was found in 44.25% (50/113) of the endometrial cancer samples, which was significantly correlated with a poor overall survival rate (p = 0.035). High-level CD44 expression was found in 35.4% (40/113) of the cases and was also correlated with a poor overall survival rate (p = 0.035). A simultaneous high expression of both markers was correlated with an extremely poor overall survival (p = 0.013). Our results show that tumors with higher expressions of both ALDH1 and CD44 were related to a poorer overall survival rate among EC patients. The combination of ALDH1 and CD44 could be a promising marker for developing additional targeted therapy for severe endometrial cancers.

Citing Articles

Role of Liquid Biopsy in Oral Premalignant and Malignant Lesions: Correlation with CD24 and CD44 Expression in Early Diagnosis of Oral Cancer.

Hemavathy O, Marimuthu Ramaswamy M, Mohana Priya C, Bhardwaj S J Maxillofac Oral Surg. 2025; 24(1):207-212.

PMID: 39902448 PMC: 11787126. DOI: 10.1007/s12663-024-02398-9.

Effect of ALDH1A1 and CD44 on Survival and Disease Recurrence in Patients With Osteosarcoma.

Haffner M, Saiz Jr A, Darrow M, Judge S, Laun T, Arora A Cureus. 2024; 16(1):e52404.

PMID: 38371078 PMC: 10869251. DOI: 10.7759/cureus.52404.

A Narrative Review on CD44's Role in Glioblastoma Invasion, Proliferation, and Tumor Recurrence.

Inoue A, Ohnishi T, Nishikawa M, Ohtsuka Y, Kusakabe K, Yano H Cancers (Basel). 2023; 15(19).

PMID: 37835592 PMC: 10572085. DOI: 10.3390/cancers15194898.

Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer.

Huang P, Fan X, Yu H, Zhang K, Li H, Wang Y J Transl Med. 2023; 21(1):94.

PMID: 36750868 PMC: 9906873. DOI: 10.1186/s12967-022-03851-4.

Computational approaches for discovering significant microRNAs, microRNA-mRNA regulatory pathways, and therapeutic protein targets in endometrial cancer.

Ajabnoor G, Alsubhi F, Shinawi T, Habhab W, Albaqami W, Alqahtani H Front Genet. 2023; 13:1105173.

PMID: 36704357 PMC: 9872035. DOI: 10.3389/fgene.2022.1105173.

References

Hidalgo A, Pina P, Guerrero G, Lazos M, Salcedo M . A simple method for the construction of small format tissue arrays. J Clin Pathol. 2003; 56(2):144-6. PMC: 1769880. DOI: 10.1136/jcp.56.2.144. View

Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z . ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest. 2009; 90(2):234-44. PMC: 3552330. DOI: 10.1038/labinvest.2009.127. View

Abdalla N, Piorkowski R, Slomka A, Kania M, Sawicki W, Cendrowski K . Analysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer. Contemp Oncol (Pozn). 2017; 20(6):463-467. PMC: 5320459. DOI: 10.5114/wo.2016.65606. View

Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q . Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One. 2010; 5(4):e10277. PMC: 2858084. DOI: 10.1371/journal.pone.0010277. View

Armstrong L, Stojkovic M, Dimmick I, Ahmad S, Stojkovic P, Hole N . Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells. 2004; 22(7):1142-51. DOI: 10.1634/stemcells.2004-0170. View

Huang R, Li X, Holm R, Trope C, Nesland J, Suo Z . The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study. BMC Cancer. 2015; 15:502. PMC: 4494797. DOI: 10.1186/s12885-015-1513-5. View

Januchowski R, Wojtowicz K, Zabel M . The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother. 2013; 67(7):669-80. DOI: 10.1016/j.biopha.2013.04.005. View

Corti S, Locatelli F, Papadimitriou D, Donadoni C, Salani S, Del Bo R . Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells. 2005; 24(4):975-85. DOI: 10.1634/stemcells.2005-0217. View

Rasheed Z, Yang J, Wang Q, Kowalski J, Freed I, Murter C . Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010; 102(5):340-51. PMC: 2831049. DOI: 10.1093/jnci/djp535. View

10.

Tanei T, Morimoto K, Shimazu K, Kim S, Tanji Y, Taguchi T . Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009; 15(12):4234-41. DOI: 10.1158/1078-0432.CCR-08-1479. View

11.

Burke W, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye A . Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014; 134(2):385-92. DOI: 10.1016/j.ygyno.2014.05.018. View

12.

Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z . Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19(2):327-37. PMC: 3544173. DOI: 10.1158/1055-9965.EPI-09-0865. View

13.

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

14.

Liu D, Ren C, Yuan X, Zhang L, Liu J, Liu Q . ALDH1 expression is correlated with pathologic grade and poor clinical outcome in patients with astrocytoma. J Clin Neurosci. 2012; 19(12):1700-5. DOI: 10.1016/j.jocn.2012.01.036. View

15.

Rao Q, Yao T, Zhang B, Lin R, Chen Z, Zhou H . Expression and functional role of ALDH1 in cervical carcinoma cells. Asian Pac J Cancer Prev. 2012; 13(4):1325-31. DOI: 10.7314/apjcp.2012.13.4.1325. View

16.

Balicki D . Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2008; 1(5):485-7. DOI: 10.1016/j.stem.2007.10.015. View

17.

Basakran N . CD44 as a potential diagnostic tumor marker. Saudi Med J. 2015; 36(3):273-9. PMC: 4381009. DOI: 10.15537/smj.2015.3.9622. View

18.

Black W, Stagos D, Marchitti S, Nebert D, Tipton K, Bairoch A . Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature. Pharmacogenet Genomics. 2009; 19(11):893-902. PMC: 3356695. DOI: 10.1097/FPC.0b013e3283329023. View

19.

Jiang T, Huang L, Zhang S . Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer. 2015; 15:396. PMC: 4438478. DOI: 10.1186/s12885-015-1260-7. View

20.

Wang Y, Han C, Teng F, Bai Z, Tian W, Xue F . Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer. Int J Gynaecol Obstet. 2017; 136(1):58-63. DOI: 10.1002/ijgo.12010. View